[1] Bray F, Laversanne M, Sung H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. [2] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [3] Han B, Zheng R, Zeng H, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. [4] Chow LQM.Head and neck cancer[J]. N Engl J Med, 2020, 382(1): 60-72. [5] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [6] Warnakulasuriya S.Global epidemiology of oral and oropharyngeal cancer[J]. Oral Oncol, 2009, 45(4-5): 309-316. [7] Pfister DG, Spencer S, Brizel DM, et al.Head and neck cancers, version 2.2014. Clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2014, 12(10): 1454-1487. [8] Siegel RL, Giaquinto AN, Jemal A.Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. [9] Lee YS, Dutta A.MicroRNAs in cancer[J]. Annu Rev Pathol, 2009, 4: 199-227. [10] 秦晓丹,孙慧玲,潘蓓,等. miR-1229-3p 抑制结直肠癌疾病进展及作为潜在生物标志物的研究[J]. 诊断学理论与实践,2023, 22(5): 429-440. Qin XD, Sun HL, Pan B, et al.miR-1229-3p inhibits the malignant progression of colorectal cancer and serves as a potential biomarker[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(5): 429-440. [11] Rupaimoole R, Slack FJ.MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3): 203-222. [12] Wen Z, Huang G, Lai Y, et al.Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer[J]. Clin Transl Oncol, 2022, 24(5): 909-918. [13] Huo X, Wang K, Yao B, et al.Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma[J]. Bmc Cancer, 2023, 23(1): 1152. [14] Towle R, Dickman CTD, MacLellan S A, et al. Identification of a serum-based microRNA signature that detects recurrent oral squamous cell carcinoma before it is clinically evident[J]. Brit J Cancer, 2023, 129(11): 1810-1817. [15] 吕飞飞,李昆珊,胡燕,等. circVAPA 通过 miR-125b/HOXA7 轴逆转口腔癌细胞化疗耐药的机制研究[J]. 现代肿瘤医学, 2023, 31(8): 1398-1404. Lyu FF, Li KS, Hu Y, et al.Mechanism of circVAPA in reversing chemoresistance of oral cancer cells through miR-125b/HOXA7 axis[J]. Journal of Modern Oncology, 2023, 31(8): 1398-1404. [16] Mete O, Wenig BM.Update from the 5th Edition of the World Health Organization classification of head and neck tumors: overview of the 2022 WHO Classification of head and neck neuroendocrine neoplasms[J]. Head Neck Pathol, 2022, 16(1): 123-142. [17] Jiang M, Yang Y, Niu L, et al.MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2[J]. J Immunother Cancer, 2022, 10(11): e005241. [18] Ferraresso M, Bailey S, Alonso-Crisostomo L, et al.Replenishing co-downregulated miR-100-5p and miR-125b-5p in malignant germ cell tumors causes growth inhibition through cell cycle disruption[J]. Mol Oncol, 2025, 19(4): 1203-1228. [19] Chen YF, Wei YY, Yang CC, et al.miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A[J]. Redox Biol, 2019, 22: 101140. [20] Yu Y, MohamedAl-Sharani H, Zhang B. EZH2-mediated SLC7A11 upregulation via miR-125b-5p represses ferroptosis of TSCC[J]. Oral Dis, 2023, 29(3): 880-891. [21] Wu M, Gao X, Tang Y, et al.Cbl-b inhibited CD4+ T cell activation by regulating the expression of miR-99a/miR-125b[J]. Int Immunopharmacol, 2023, 115: 109677. [22] Song L, Wang X, Qu X, et al.Transcription factor specificity protein 1 regulates inflammation and fibrin deposition in nasal polyps via the regulation of microRNA-125b and the Wnt/β-catenin signaling pathway[J]. Inflammation, 2022, 45(3): 1118-1132. [23] Rambow F, Bechadergue A, Luciani F, et al.Regulation of melanoma progression through the TCF4/miR-125b/NEDD9 cascade[J]. J Invest Dermatol, 2016, 136(6): 1229-1237. [24] Manfè V, Biskup E, Willumsgaard A, et al.cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas[J]. PLoS One, 2013, 8(3): e59390. [25] Zeng CW, Zhang XJ, Lin KY, et al.Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways[J]. Mol Pharmacol, 2012, 81(4): 578-586. [26] Lin KY, Ye H, Han BW, et al.Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma[J]. Oncogene, 2016, 35(26): 3376-3386. [27] Zhang L, Ge Y, Fuchs E. miR-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival[J]. Gene Dev, 2014, 28(22): 2532-2546. [28] Semenza GL.Targeting HIF-1 for cancer therapy[J]. Nat Rev Cancer, 2003, 3(10): 721-732. [29] Dhillon AS, Hagan S, Rath O, et al.MAP kinase signalling pathways in cancer[J]. Oncogene, 2007, 26(22): 3279-3290. [30] Xue C, Yao Q, Gu X, et al.Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer[J]. Signal Transduct Tar, 2023, 8(1): 204. [31] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. [32] Cohen EEW, Bell RB, Bifulco CB, et al.The Society for Immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)[J]. J Immunother Cancer, 2019, 7(1): 184. [33] Philip M, Schietinger A.CD8+ T cell differentiation and dysfunction in cancer[J]. Nat Rev Immunol, 2022, 22(4): 209-223. [34] Gołabek K, Hudy D, Swietek A, et al.miR-125b-5p, miR-155-3p, and miR-214-5p and target E2F2 gene in oral squamous cell carcinoma[J]. Int J Mol Sci, 2023, 24(7): 6320. |